Welcome to the international HTA database

Showing [16381 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2022	Malaysian Health Technology Assessment (MaHTAS)	Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for non-small cell lung cancer
2022	Malaysian Health Technology Assessment (MaHTAS)	Immunotherapy for PD-L1 positive advanced non-small cell lung cancer
2022	Malaysian Health Technology Assessment (MaHTAS)	Molecular profiling assays in early breast cancer
2022	Malaysian Health Technology Assessment (MaHTAS)	Tertiary care virtual online consultation between doctor and patient
2022	Institute for Clinical and Economic Review (ICER)	The next generation of rare disease drug policy: ensuring both innovation and affordability
2022	Institute for Clinical and Economic Review (ICER)	California unsupported price increase report; an evaluation of drug price increases during 2020 in California
2022	Institute for Clinical and Economic Review (ICER)	Unsupported price increase report: unsupported price increases occurring in 2021
2022	Institute for Clinical and Economic Review (ICER)	Novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects [updated Sept 29, 2023]
2022	Institute for Clinical and Economic Review (ICER)	AMX0035 and oral edaravone for amyotrophic lateral sclerosis
2022	Institute for Clinical and Economic Review (ICER)	Medications for obesity management: effectiveness and value
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Systemic thrombolysis and endovascular therapy for large vessel occlusion acute ischemic stroke
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Systemic thrombolysis by alteplase for acute ischemic stroke
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Dapagliflozin for chronic kidney disease
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Internet-delivered cognitive behavioural therapy in the treatment of chronic non-cancer pain
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Peer support programs for youth mental health
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Adalimumab for the treatment of pediatric populations with non-infectious uveitis
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Adalimumab for the treatment of adults with non-infectious uveitis
2022	Agency for Healthcare Research and Quality (AHRQ)	Transitions of care from pediatric to adult services for children with special healthcare needs
2022	Agency for Healthcare Research and Quality (AHRQ)	Telehealth for women's preventive services
2022	Agency for Healthcare Research and Quality (AHRQ)	Schedule of visits and televisits for routine antenatal care
2022	Agency for Healthcare Research and Quality (AHRQ)	Noninvasive nonpharmacological treatment for chronic pain
2022	Agency for Healthcare Research and Quality (AHRQ)	Models of care that include primary care for adult survivors of childhood cancer: a realist review
2022	Agency for Healthcare Research and Quality (AHRQ)	Maternal and child outcomes associated with the Special Supplemental Nutrition Program for women, infants, and children (WIC)
2022	Agency for Healthcare Research and Quality (AHRQ)	Management of infantile epilepsies
2022	Agency for Healthcare Research and Quality (AHRQ)	Infection prevention and control for the emergency medical services and 911 workforce
2022	Agency for Healthcare Research and Quality (AHRQ)	Improving rural health through telehealth-guided provider-to-provider communication
2022	Agency for Healthcare Research and Quality (AHRQ)	Evaluation of mental health mobile applications
2022	Agency for Healthcare Research and Quality (AHRQ)	Diagnostic errors in the emergency department: a systematic review
2022	Agency for Healthcare Research and Quality (AHRQ)	Antibody response following SARS-CoV-2 infection and implications for immunity: a living rapid review
2022	Agency for Healthcare Research and Quality (AHRQ)	Acute treatments for episodic migraine
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Pegcetacoplan (paroxysmal nocturnal haemoglobinuria, pretreated patients)]
2022	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Suvanto Care Safety Service
2022	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Unipercare service for home care and service centres
2022	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	The Orla INR Remote Monitoring
2022	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Hygga Flow Enterprise Resource Planning System
2022	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Monidor solution for the implementation of intravenous fluid therapy
2022	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Smila Care Service
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	The utilization and national variation of plain x-ray services by Australian residents of long-term care facilities
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Residents' perspectives of mobile X-ray services in support of healthcare-in-place in residential aged care facilities: a qualitative study.
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Stakeholders' perspectives of mobile x-ray services in support of healthcare-in-place in residential aged care facilities: a qualitative study
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Update: guidelines on the preoperative diagnostic workup for COVID-19
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Mesh versus non-mesh repair of groin hernias: a rapid review
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Impact of COVID-19, gender, race, specialty and seniority on mental health during surgical training: an international study
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Achieving safe surgery after COVID-19 vaccination
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Quality improvement strategies in trauma care: review and proposal of 31 novel quality indicators
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Hepatic and portal vein embolization prior to major hepatectomy
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Microwave ablation for liver tumours
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Oral anticoagulants for prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation. [Protocol]
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Calcitonin gene-related peptide antagonists for the prevention of migraine [Protocol]
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Denosumab (Prolia) for the treatment of osteoporosis
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Revascularisation versus optimal medical therapy (OMT) for the treatment of chronic coronary syndrome (CCS). [Protocol]
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Folate testing. [Protocol]
2022	Scottish Health Technologies Group (SHTG)	A national radiology information system (RIS) for Scotland: perceived benefits and constraints to implementation
2022	Scottish Health Technologies Group (SHTG)	The Psychology Adding Value – Epilepsy Screening (PAVES) and early intervention for children and young people with epilepsy at risk of mental health problems
2022	WorkSafeBC	Lose-dose naltrexone as treatment for post-COVID conditions
2022	WorkSafeBC	Convergence insufficiency and COVID-19 infection
2022	WorkSafeBC	Oral collagen supplements for shoulder sprain strain
2022	WorkSafeBC	Inpatient versus outpatient programs as treatment for PTSD
2022	WorkSafeBC	Vision therapy as treatment for traumatic brain injury: 2022 update
2022	WorkSafeBC	Tinnitus and the COVID-19 vaccine
2022	WorkSafeBC	Environmental exposure to respirable particles and estimated risk of sarcoidosis
2022	Agency for Care Effectiveness (ACE)	GLP-1 receptor agonist injections for treating type 2 diabetes mellitus
2022	Agency for Care Effectiveness (ACE)	Recombinant blood products for prophylaxis and management of haemophilia A and B
2022	Agency for Care Effectiveness (ACE)	Ciclosporin 0.1% eye drops for treating severe vernal keratoconjunctivitis
2022	Agency for Care Effectiveness (ACE)	Acarbose for treating type 2 diabetes mellitus
2022	Agency for Care Effectiveness (ACE)	Dolutegravir with lamivudine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection
2022	Agency for Care Effectiveness (ACE)	Sodium zirconium cyclosilicate for treating hyperkalaemia
2022	Agency for Care Effectiveness (ACE)	Ciclosporin 0.1% eye drops for treating severe keratitis in dry eye disease
2022	Agency for Care Effectiveness (ACE)	Nicotine replacement therapies to aid smoking cessation
2022	Agency for Care Effectiveness (ACE)	Robot-assisted endovascular intervention systems for coronary artery disease and other vascular diseases
2022	Agency for Care Effectiveness (ACE)	Magnetic resonance image guided radiation therapy for patients with cancer
2022	Agency for Care Effectiveness (ACE)	Cooral System for the prevention of oral mucositis
2022	Health Sciences Institute in Aragon (IACS)	[Non-perforating deep sclerectomy (NPDS) in open angle primary glaucoma (POAG)]
2022	Health Technology Wales (HTW)	Wearable cardioverter-defibrillators for people at risk of cardiac death
2022	Health Technology Wales (HTW)	Photobiomodulation for the prevention and treatment of oral mucositis and radiation dermatitis associated with cancer treatment
2022	Health Technology Wales (HTW)	Closed loop systems for the management of type 1 diabetes mellitus in adults and children
2022	Health Technology Wales (HTW)	Continuous topical oxygen therapy to treat people with chronic non-healing and complex diabetic foot ulcers
2022	Health Technology Wales (HTW)	Left atrial appendage occlusion in patients with atrial fibrillation
2022	Malaysian Health Technology Assessment (MaHTAS)	Mesenchymal stem cells for retinitis pigmentosa and other degenerative retina disease
2022	Malaysian Health Technology Assessment (MaHTAS)	Sublingual immunotherapy (SLIT) for atopy (allergic rhinitis, eczema and asthma)
2022	Malaysian Health Technology Assessment (MaHTAS)	Transcutaneous oxygen pressure monitoring (TcPO2)
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Somatrogon (growth disturbance due to growth hormone deficiency, ≥ 3 to < 18 years]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Voretigene Neparvovec (reassessment after the deadline: inherited retinal dystrophy)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Idebenone (reassessment after the deadline: Leber's Hereditary Optic Neuropathy)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Glucarpidase (reduction of toxic plasma methotrexate concentrations; aged 28 days and older)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tebentafusp (uveal melanoma, HLA-A*02:01-positive)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Avapritinib (new therapeutic indication: systemic mastocytosis, after at least 1 prior therapy)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Voxelotor (haemolytic anaemia in sickle cell disease, monotherapy or combination with hydroxycarbamide, ≥ 12 years)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tisagenlecleucel (new therapeutic indication: follicular lymphoma, pretreated patients)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Polatuzumab Vedotin (new therapeutic indication: diffuse large B-cell lymphoma (DLBCL), combination with rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP))]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Setmelanotide (obesity and control of hunger, POMC, PCSK1 or LEPR-deficiency obesity, ≥ 6 years)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Mosunetuzumab (follicular lymphoma, after ≥ 2 prior therapies)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Cerliponase Alfa - reassessment after the deadline (type 2 neuronal ceroid lipofuscinosis)]
2022	Malaysian Health Technology Assessment (MaHTAS)	First line targeted therapy for advanced hepatocellular carcinoma (aHCC)
2022	Malaysian Health Technology Assessment (MaHTAS)	Early cancer detection test for lung (EarlyCDT-Lung)
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Perinatal and infant mental health care models and pathways
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Conductive intravesical chemohyperthermia with mitomycin in non-muscle invasive bladder cancer: review of guidelines and ongoing research]
2022	NIHR Health Services and Delivery Research programme	Understanding the potential factors affecting carers’ mental health during end-of-life home care: a meta synthesis of the research literature
2022	NIHR Health Technology Assessment programme	Determining optimal strategies for primary prevention of cardiovascular disease: systematic review of cost-effectiveness analyses in the United Kingdom
2022	NIHR Health Technology Assessment programme	Oral nutritional interventions in frail older people who are malnourished or at risk of malnutrition: a systematic review